US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PELTHOS THERAPEUTICS INC

25.14

-1.3200-4.99%

Post-market: 24.65-0.4900-1.95%17:21 EST

Volume:58.00K

Turnover:1.40M

Market Cap:76.97M

PE:-1.69

High:26.95

Open:26.67

Low:21.61

Close:26.46

52wk High:54.29

52wk Low:5.51

Shares:3.06M

Float Shares:2.62M

Volume Ratio:2.20

T/O Rate:2.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-14.8358

EPS(LYR):-14.2710

ROE:-83.00%

ROA:-20.64%

PB:1.32

PE(LYR):-1.76

Loading ...

Overview Company News Filings

Pelthos Therapeutics Director Ezra M. Friedberg Sells Common Shares

Pelthos Therapeutics (PTHS) Gets a Buy from Roth MKM

Pelthos Therapeutics Inc. Announces Date for Upcoming Annual Shareholder Meeting

Pelthos Therapeutics reports $7.4 million in third quarter revenue

Pelthos Therapeutics acquires Xepi Cream from Biofrontera, Ferrer

Pelthos Therapeutics Acquires Xepi for $4.2 Million Upfront

Pelthos Therapeutics Inc - to Pay $3.0 Mln to Biofrontera and $1.2 Mln to Ferrer

THOMSON REUTERS

Pelthos Therapeutics (PTHS) Gets a Buy from Oppenheimer

Pelthos Therapeutics Inc. Releases Q4 2025 Corporate Presentation

Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment

Pelthos Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $50

THOMSON REUTERS

Pelthos Therapeutics Initiated at Outperform by Oppenheimer

Oppenheimer Initiates Pelthos Therapeutics at Outperform With $50 Price Target

MT Newswires Live

BRIEF-Pelthos Therapeutics Inc Files For Offering Of Up To 8.14 Million Common Shares By The Selling Stockholders

Pelthos Therapeutics Inc Files for Offering of up to 8.14 Mln Common Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS

Press Release: Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update

Pelthos Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO and President Scott M. Plesha

Pelthos Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Sai Rangarao

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires Live

Top Midday Gainers

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PTHS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTHS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTHS\",,,,,undefined,":{"symbol":"PTHS","market":"US","secType":"STK","nameCN":"PELTHOS THERAPEUTICS INC","latestPrice":25.14,"timestamp":1764709200000,"preClose":26.46,"halted":0,"volume":58002,"hourTrading":{"tag":"盘后","latestPrice":24.65,"preClose":25.14,"latestTime":"17:21 EST","volume":12,"amount":298.249992,"timestamp":1764714119525},"delay":0,"floatShares":2623100,"shares":3061681,"eps":-14.835798,"marketStatus":"Post-Mkt","change":-1.32,"latestTime":"12-02 17:47:06 EST","open":26.67,"high":26.95,"low":21.61,"amount":1401982.9305719999,"amplitude":0.201814,"askPrice":35.81,"askSize":100,"bidPrice":24.65,"bidSize":44,"shortable":0,"etf":0,"ttmEps":-14.835798,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"listingDate":1708059600000,"exchange":"AMEX","adjPreClose":26.46,"preHourTrading":{"tag":"盘前","latestPrice":27.49,"preClose":26.46,"latestTime":"09:28 EST","volume":6,"amount":164.95000199999998,"timestamp":1764685737598},"postHourTrading":{"tag":"盘后","latestPrice":24.65,"preClose":25.14,"latestTime":"17:21 EST","volume":12,"amount":298.249992,"timestamp":1764714119525},"volumeRatio":2.197145},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTHS\",,,,,undefined,":{"symbol":"PTHS","floatShares":2623100,"roa":"-20.64%","roe":"-83.00%","lyrEps":-14.271021,"volumeRatio":2.197145,"shares":3061681,"dividePrice":0,"high":26.95,"amplitude":0.201814,"preClose":26.46,"low":21.61,"week52Low":5.513,"pbRate":"1.32","psRate":"10.39","week52High":54.29,"institutionHeld":0,"latestPrice":25.14,"committee":-0.388889,"eps":-14.835798,"divideRate":0,"volume":58002,"delay":0,"ttmEps":-14.835798,"open":26.67,"prevYearClose":6.41,"prevWeekClose":28.4,"prevMonthClose":28.4,"prevQuarterClose":28,"fiveDayClose":27.53,"twentyDayClose":34.21,"sixtyDayClose":32.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTHS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"PTHS","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-5.3},{"market":"US","date":"2025-07-02","symbol":"PTHS","defaultRemindTime":1751463000000,"type":"split","dateTimestamp":1751428800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTHS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTHS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1764306000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PTHS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PTHS","date":"2025-12-01","current":-1.783524,"percent":0.580952,"low":-12.702408,"twenty":-11.1077,"median":-7.894967,"eighty":-1.793992,"high":-1.189404,"avg":-6.564203,"sd":4.26405,"marketCap":86951740},"quantilePoints":[{"date":"2025-07-03","current":-1.450338,"twenty":-1.398151,"median":-1.319871,"eighty":-1.241591,"marketCap":10675383},{"date":"2025-07-11","current":-2.372872,"twenty":-2.216593,"median":-1.475876,"eighty":-1.450338,"marketCap":17465810},{"date":"2025-07-18","current":-1.983069,"twenty":-1.968731,"median":-1.794665,"eighty":-1.455446,"marketCap":14596616},{"date":"2025-07-25","current":-1.97142,"twenty":-1.96909,"median":-1.819083,"eighty":-1.509032,"marketCap":14510870},{"date":"2025-08-01","current":-1.895251,"twenty":-1.972137,"median":-1.894355,"eighty":-1.668896,"marketCap":13950222},{"date":"2025-08-08","current":-1.785927,"twenty":-1.971241,"median":-1.88181,"eighty":-1.778579,"marketCap":13145529},{"date":"2025-08-15","current":-1.383693,"twenty":-1.968373,"median":-1.828044,"eighty":-1.653842,"marketCap":12505731},{"date":"2025-08-22","current":-1.565412,"twenty":-1.958336,"median":-1.793992,"eighty":-1.534031,"marketCap":14148098},{"date":"2025-08-29","current":-7.738365,"twenty":-1.968373,"median":-1.78996,"eighty":-1.553735,"marketCap":69938867},{"date":"2025-09-05","current":-10.936036,"twenty":-1.983069,"median":-1.813483,"eighty":-1.562493,"marketCap":98839226},{"date":"2025-09-12","current":-10.771103,"twenty":-7.559968,"median":-1.868816,"eighty":-1.565412,"marketCap":97348576},{"date":"2025-09-19","current":-11.212045,"twenty":-9.357396,"median":-1.887634,"eighty":-1.641655,"marketCap":101333783},{"date":"2025-09-26","current":-11.188484,"twenty":-10.771103,"median":-1.911381,"eighty":-1.642041,"marketCap":101120833},{"date":"2025-10-03","current":-8.961188,"twenty":-10.771103,"median":-1.965147,"eighty":-1.648609,"marketCap":80990668},{"date":"2025-10-10","current":-8.414925,"twenty":-10.626367,"median":-1.972316,"eighty":-1.659169,"marketCap":76053575},{"date":"2025-10-17","current":-9.593014,"twenty":-10.434506,"median":-2.154672,"eighty":-1.70259,"marketCap":86701075},{"date":"2025-10-24","current":-11.663085,"twenty":-10.626367,"median":-7.559968,"eighty":-1.70259,"marketCap":105410254},{"date":"2025-10-31","current":-11.19185,"twenty":-10.777835,"median":-7.80905,"eighty":-1.706174,"marketCap":101151254},{"date":"2025-11-07","current":-12.702408,"twenty":-10.936036,"median":-7.98408,"eighty":-1.777862,"marketCap":114803587},{"date":"2025-11-14","current":-11.772301,"twenty":-11.111066,"median":-8.995487,"eighty":-1.781447,"marketCap":106397338},{"date":"2025-11-21","current":-3.765213,"twenty":-11.111066,"median":-8.414925,"eighty":-1.785927,"marketCap":88788749},{"date":"2025-11-28","current":-3.687312,"twenty":-11.108373,"median":-7.960687,"eighty":-1.792379,"marketCap":86951740},{"date":"2025-12-01","current":-3.687312,"twenty":-11.1077,"median":-7.894967,"eighty":-1.793992,"marketCap":86951740}],"updateTime":1764677312727},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTHS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586261442","title":"Pelthos Therapeutics Director Ezra M. Friedberg Sells Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586261442","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586261442?lang=en_us&edition=fundamental","pubTime":"2025-11-27 01:37","pubTimestamp":1764178661,"startTime":"0","endTime":"0","summary":"Ezra M. Friedberg, a Director of Pelthos Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL3y2sTb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Pelthos Therapeutics Director Ezra M. Friedberg Sells Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2586449447","title":"Pelthos Therapeutics (PTHS) Gets a Buy from Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2586449447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586449447?lang=en_us&edition=fundamental","pubTime":"2025-11-25 13:35","pubTimestamp":1764048915,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics received a Buy rating and a $57.00 price target from Roth MKM analyst Jonathan Aschoff today. According to TipRanks, Aschoff i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pelthos-therapeutics-pths-gets-a-buy-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pelthos-therapeutics-pths-gets-a-buy-from-roth-mkm-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2583682180","title":"Pelthos Therapeutics Inc. Announces Date for Upcoming Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682180","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682180?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:50","pubTimestamp":1763157043,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has announced that it will hold its 2025 Annual Meeting of Shareholders online on December 17, 2025. Shareholders will have the opportunity to consider and vote on several items during the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL8Gy4Nj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2583356458","title":"Pelthos Therapeutics reports $7.4 million in third quarter revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2583356458","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583356458?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:50","pubTimestamp":1763034644,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. reported total revenue of $7.4 million for the third quarter ended September 30, 2025, compared to no revenue in the same period of 2024. Net product revenues from the commercial launch of ZELSUVMI, its FDA-approved at-home treatment for molluscum contagiosum, were $7.1 million, while license and collaboration revenues were $0.3 million. The company reported a net loss of $16.2 million, or $5.30 per basic and fully diluted common share. Cash and cash equivalents increased to $14.2 million as of September 30, 2025, from $0.5 million at the end of 2024, following a $50.1 million equity private placement. During the quarter, 2,716 units of ZELSUVMI were dispensed by 1,169 unique prescribers. The merger of Channel Therapeutics Corporation and LNHC, Inc. was completed to form Pelthos Therapeutics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL1kt5HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2581883456","title":"Pelthos Therapeutics acquires Xepi Cream from Biofrontera, Ferrer","url":"https://stock-news.laohu8.com/highlight/detail?id=2581883456","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581883456?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:10","pubTimestamp":1762521026,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics (PTHS) has acquired the U.S. commercialization rights to XepiCream, 1%, from Biofrontera Inc. (BFRI) and Ferrer Internacional....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pelthos-therapeutics-acquires-xepi-cream-from-biofrontera-ferrer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pelthos-therapeutics-acquires-xepi-cream-from-biofrontera-ferrer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BFRI","PTHS","BK4539","LENZ"],"gpt_icon":0},{"id":"2581887868","title":"Pelthos Therapeutics Acquires Xepi for $4.2 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2581887868","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581887868?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:02","pubTimestamp":1762520555,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has acquired Xepi  Cream, 1%, an FDA-approved topical treatment for impetigo, expanding its dermatology portfolio alongside its novel molluscum contagiosum treatment, ZELSUVMI. Xepi addresses a critical unmet need in antibiotic-resistant skin infections, particularly those caused by staph and strep bacteria, and is most commonly used in pediatric patients. The company plans to relaunch Xepi in the U.S. and will use proceeds from a recently completed $18 million private convertible notes financing to support the acquisition, as well as to accelerate commercialization efforts for ZELSUVMI and for general working capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the origi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL13205J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2581438888","title":"Pelthos Therapeutics Inc - to Pay $3.0 Mln to Biofrontera and $1.2 Mln to Ferrer","url":"https://stock-news.laohu8.com/highlight/detail?id=2581438888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581438888?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:00","pubTimestamp":1762520400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA5S2GTM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2580243156","title":"Pelthos Therapeutics (PTHS) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2580243156","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580243156?lang=en_us&edition=fundamental","pubTime":"2025-11-04 00:57","pubTimestamp":1762189035,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Jeff Jones maintained a Buy rating on Pelthos Therapeutics today and set a price target of $50.00. The company’s shares opened ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pelthos-therapeutics-pths-gets-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pelthos-therapeutics-pths-gets-a-buy-from-oppenheimer-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4127","PTHS","OPY"],"gpt_icon":0},{"id":"2575292205","title":"Pelthos Therapeutics Inc. Releases Q4 2025 Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2575292205","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575292205?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:46","pubTimestamp":1760442419,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL7pz49T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2564300314","title":"Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2564300314","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564300314?lang=en_us&edition=fundamental","pubTime":"2025-09-04 04:50","pubTimestamp":1756932625,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL7K5rvN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2564077038","title":"Pelthos Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2564077038","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564077038?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:56","pubTimestamp":1756817792,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nFWN3UP0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2564810807","title":"Pelthos Therapeutics Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2564810807","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564810807?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:30","pubTimestamp":1756816200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTHS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 02, 2025 08:30 ET (12:30 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","OPY","PTHS"],"gpt_icon":0},{"id":"2564603806","title":"Oppenheimer Initiates Pelthos Therapeutics at Outperform With $50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2564603806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564603806?lang=en_us&edition=fundamental","pubTime":"2025-09-02 18:44","pubTimestamp":1756809876,"startTime":"0","endTime":"0","summary":"Oppenheimer Initiates Pelthos Therapeutics at Outperform With $50 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTHS","LENZ","OPY"],"gpt_icon":0},{"id":"2563698900","title":"BRIEF-Pelthos Therapeutics Inc Files For Offering Of Up To 8.14 Million Common Shares By The Selling Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2563698900","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563698900?lang=en_us&edition=fundamental","pubTime":"2025-08-29 04:27","pubTimestamp":1756412867,"startTime":"0","endTime":"0","summary":"BRIEF-Pelthos Therapeutics Inc Files For Offering Of Up To 8.14 Million Common Shares By The Selling StockholdersAug 28  - Pelthos Therapeutics Inc PTHS.A:PELTHOS THERAPEUTICS INC FILES FOR OFFERING OF UP TO 8.14 MILLION COMMON SHARES BY THE SELLING STOCKHOLDERS - SEC FILINGFurther company coverage: PTHS.A ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UK1UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2563682066","title":"Pelthos Therapeutics Inc Files for Offering of up to 8.14 Mln Common Shares by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2563682066","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563682066?lang=en_us&edition=fundamental","pubTime":"2025-08-29 04:07","pubTimestamp":1756411657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UK1UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2560622902","title":"Press Release: Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2560622902","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560622902?lang=en_us&edition=fundamental","pubTime":"2025-08-18 20:00","pubTimestamp":1755518400,"startTime":"0","endTime":"0","summary":"-- Files Quarterly Report on Form 10-Q detailing financial results for. legacy operations for the three and six months ended June 30, 2025. -- Strong physician response following successful launch of ZELSUVMI.  topical gel 10.3%, the first and only FDA-approved at-home. treatment for molluscum contagiosum for patients one year of age and. Completed the Merger with Channel Therapeutics and closed the $50.1 million private placement financing. As previously announced, on July 1, 2025, Pelthos completed its Merger with and into a wholly owned subsidiary of Channel Therapeutics Corporation and closed a $50.1 million private placement to support the commercial launch of ZELSUVMI. The combined company now operates under the name Pelthos Therapeutics Inc.On July 10, 2025, Pelthos launched ZELSUVMI, the first and only prescription therapy approved by the U.S. Food and Drug Administration  for use at home by patients, parents, and caregivers to treat molluscum infections, a highly contagious vi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4585","PTHS","BK4539","BK4099","BK4555","TM","BK4139","BK4007","LENZ","BK4588","03160"],"gpt_icon":0},{"id":"2553221965","title":"Pelthos Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO and President Scott M. Plesha","url":"https://stock-news.laohu8.com/highlight/detail?id=2553221965","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553221965?lang=en_us&edition=fundamental","pubTime":"2025-07-24 09:14","pubTimestamp":1753319666,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing identifies Scott M. Plesha as the beneficial owner, who holds the position of CEO and President, as well as a Director, of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL5RZJCq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139"],"gpt_icon":0},{"id":"2553650407","title":"Pelthos Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Commercial Officer Sai Rangarao","url":"https://stock-news.laohu8.com/highlight/detail?id=2553650407","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553650407?lang=en_us&edition=fundamental","pubTime":"2025-07-22 08:26","pubTimestamp":1753143968,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Inc. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing names Sai Rangarao as the beneficial owner, who holds the position of Chief Commercial Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL1xkJDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTHS"],"gpt_icon":0},{"id":"2550753466","title":"Sector Update: Health Care Stocks Rise Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2550753466","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550753466?lang=en_us&edition=fundamental","pubTime":"2025-07-11 03:57","pubTimestamp":1752177431,"startTime":"0","endTime":"0","summary":"Health care stocks advanced late Thursday afternoon, with the NYSE Health Care Index rising 0.9% and the Health Care Select Sector SPDR Fund (XLV) gaining 0.7%.The iShares Biotechnology ETF (IBB) incr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU1829250122.USD","BK4533","GSK.UK","BK4532","BK4588","BK4139","LU1559883803.SGD","RARE","BK4568","PTHS","LGND","MRNA","GSK","BK4534","XLV","BK4137","BK4007","IBB","BK4581","BK4535","BK4548","BK4551","LU0566484027.USD","BNTX","HCSG","BK4501"],"gpt_icon":1},{"id":"2550620740","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2550620740","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550620740?lang=en_us&edition=fundamental","pubTime":"2025-07-11 01:56","pubTimestamp":1752170198,"startTime":"0","endTime":"0","summary":"DallasNews (DALN) and Hearst said Thursday they have signed a deal under which the latter will acquire DallasNews for $14 per share in cash.Shares of DallasNews more than tripled as intraday trading v","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4111","SOL.USD.HKCC","LGND","BK4595","BK4023","LU1559883803.SGD","LU0566484027.USD","BK4600","DALN","BK4139","PTHS"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}